Anales de la RANM

124 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 ASPIRINA EN PREVENCIÓN PRIMARIA CARDIOVASCULAR Berrazueta Fernández JR An RANM. 2023;140(02):114 - 124 26. Pignone M, Alberts MJ, Colwell JA et al. As- pirin for primary prevention of cardiovascular events in people with diabetes: a position state- ment of the American Diabetes Association, a scientific statement of the American Heart As- sociation, and an expert consensus document of the American College of Cardiology Foun- dation. Circulation. 2010; 121(24): 2694-2701. 27. Antithrombotic Trialists' (ATT) Collaboration; Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomi- sed trials. Lancet. 2009; 373(9678): 1849-1860. doi: 10.1016/S0140-6736(09)60503-1. 28. ASCEND Study Collaborative Group; Bowman L, Mafham M, Wallendszus K et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018; 379(16): 1529-1539. doi: 10.1056/NEJMoa1804988 29. McNeil JJ, Wolfe R, Woods RL et al; ASPREE Investigator Group. Effect of aspirin on car- diovascular events and bleeding in the healthy elderly. N Engl J Med. 2018; 379(16): 1509- 1518. doi: 10.1056/NEJMoa1805819 30. Gaziano JM, Brotons C, Coppolecchia R et al; ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in pa- tients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo- controlled trial. Lancet. 2018 ; 392(10152): 1036- 1046. doi: 10.1016/S0140-6736(18)31924-X 31. Shufelt Ch L, Mora S, Manson JE. A s p i r i n for the primary prevention of atherosclerotic cardiovascular disease in women. JAMA. 2022; 328(7): 672-673. doi: 10.1001/jama.2022.11951. 32. Guirguis-Blake JM, Evans CV, Perdue LA et al. Aspirin use to prevent cardiovascular disease and colorectal cancer. JAMA. 2022; 327(16): 1585-1597. 33. Arnett DK, Blumenthal RS, Albert MA et al. 2019 ACC/AHA guideline on the primary pre- vention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practi- ce Guidelines. Circulation. 2019; 140(11): e596- e646. doi:10.1161/CIR.0000000000000678 34. Visseren FLJ, Mach F, Smulders YM et al; ESC National Cardiac Societies; ESC Scientific Do- cument Group. 2021 ESC Guidelines on cardio- vascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227-3337. 35. American Diabetes Association Professional Practice Committee. 10.Cardiovascular disea- se and risk management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2021; 45(suppl 1): S144-S174. 36. Mosca L, Benjamin EJ, Berra K et al. Effecti- veness-based guidelines for the prevention of cardiovascular disease in women–2011 update: a guideline from the American Heart Association. J Am Coll Cardiol. 2011; 57(12): 1404-1423. 37. US Preventive Services Task Force. Aspirin Use to Prevent Cardiovascular Disease: US Pre- ventive Services Task Force Recommendation Statement. JAMA. 2022; 327(16): 1577-1584. doi:10.1001/jama.2022.4983 Si desea citar nuestro artículo: Berrazueta Fernández JR. Aspirina en Prevención Prima- ria Cardiovascular. An RANM. 2023;140(02): 114– 124. DOI: 10.32440/ar.2023.140.02. rev02